F. Hoffmann-La Roche Ltd v Cipla Ltd

F. Hoffmann-La Roche Ltd v Cipla Ltd is one of the most significant patent infringement cases decided by the Delhi High Court. The dispute arose in the context of pharmaceutical patents and involved competing interests between patent protection and public access to life-saving medicines. 

The case is particularly important for its interpretation of Section 3(d) of the Patents Act, 1970, the test for patent infringement, and the treatment of polymorphs in pharmaceutical patents.

The judgement has played a crucial role in shaping Indian patent jurisprudence and continues to be frequently cited in cases involving drug patents and infringement claims.

Parties to the Dispute

The dispute was between:

• F. Hoffmann-La Roche Ltd, a Swiss multinational healthcare and pharmaceutical company with operations across several countries. Roche was the holder and licensee of Indian Patent No. 196774 relating to Erlotinib Hydrochloride.
• Cipla Ltd, an Indian multinational pharmaceutical and biotechnology company engaged in manufacturing and marketing generic drugs in India and abroad.

Background of the Patent

Roche was granted Indian Patent No. 196774 (IN ’774) for a compound described as:

A novel [6,7-bis(2-methoxyethoxy) quinazolin-4-yl]-(3-ethynylphenyl) amine hydrochloride,
commonly known as Erlotinib Hydrochloride.

Roche manufactured and marketed this compound as an anti-cancer drug under the brand name TARCEVA. Erlotinib Hydrochloride was used in the treatment of certain types of cancer and was considered a life-saving drug.

Facts of F. Hoffmann-La Roche Ltd v Cipla Ltd Case

In February 2007, Roche began selling Erlotinib Hydrochloride in India under the brand name TARCEVA after obtaining the patent.

In January 2008, Roche became aware that Cipla was planning to launch a generic version of Erlotinib Hydrochloride under the brand name ERLOCIP. Cipla’s product was sold at a significantly lower price compared to Roche’s drug.

Roche filed a suit for patent infringement before the Delhi High Court in 2008, alleging that Cipla had infringed its patent IN ’774 by manufacturing and selling ERLOCIP.

Roche sought an interim injunction to restrain Cipla from manufacturing and selling the impugned drug during the pendency of the suit.

Proceedings Before the Single Judge

The matter first came up before a Single Judge of the Delhi High Court, who examined Roche’s application for interim relief.

Section 3(d) of the Patents Act

Cipla argued that Roche’s patent did not satisfy the requirements of Section 3(d) of the Patents Act, 1970, as the claimed invention did not demonstrate enhanced therapeutic efficacy.

The Single Judge rejected this contention. The Court relied on the findings of the Controller of Patents, who had earlier dealt with a pre-grant opposition filed against Roche. During the prosecution stage, Roche had submitted efficacy data to establish enhanced therapeutic efficacy.

The Controller had accepted this data and granted the patent. The Single Judge held that the invention could not be treated as non-patentable under Section 3(d), since the enhanced efficacy requirement had already been examined and accepted.

Balance of Convenience and Interim Injunction

While deciding whether an interim injunction should be granted, the Single Judge examined the principle of balance of convenience. Reference was made to earlier decisions, including:

• Roussel Uclaf v G.D. Searle & Co Ltd
• Cordis Corporation v Boston Scientific Corporation

The Court took note of the price difference between the two drugs. A month’s dosage of TARCEVA was priced at approximately Rs. 1.4 lakh, whereas ERLOCIP was available at around Rs. 46,000.

The Court held that, as between the competing public interests, access to an affordable life-saving drug had to be prioritised over the grant of an injunction affirming a patent during trial. The Court observed that monetary loss to Roche could be compensated through damages, but deprivation of access to a cheaper cancer drug could cause irreparable injury to the public.

Accordingly, the Single Judge refused to grant an interim injunction against Cipla.

However, to safeguard Roche’s interests, Cipla was directed to:

• Give an undertaking to pay damages if the suit was decreed
• Maintain proper accounts of sales
• File quarterly and annual statements of sales before the Court

Appeal Before the Division Bench

Roche challenged the decision of the Single Judge before a Division Bench of the Delhi High Court.

The Division Bench undertook a detailed examination of the scope and interpretation of Section 3(d) and its relationship with other provisions of the Patents Act.

F. Hoffmann-La Roche Ltd v Cipla Ltd Judgement

The judgment in F. Hoffmann-La Roche Ltd v Cipla Ltd is a landmark ruling on pharmaceutical patent infringement under Indian law. 

The dispute concerned Roche’s patent IN 774 for Erlotinib Hydrochloride, marketed as Tarceva, and Cipla’s generic version, Erlocip. While the Single Judge of the Delhi High Court refused interim injunction on grounds of public interest and affordability of life-saving drugs, the Division Bench later held Cipla liable for infringement. 

The Court clarified the scope of Section 3(d) of the Patents Act, recognising incremental innovation and holding that Section 3(d) cannot operate as a defence to infringement. The judgment also laid down a claim-based test for patent infringement and addressed infringement involving polymorphic forms.

Interpretation of Section 3(d)

The Division Bench clarified that Section 3(d) is not merely a provision barring patentability. Instead, it recognises incremental innovation in pharmaceutical inventions.

The Court observed that structurally similar derivatives of a known substance are presumed to be functionally similar. However, if such derivatives demonstrate enhancement of known efficacy, they qualify for examination as new products under Section 2(1)(j).

The judgement explained the statutory framework by linking:

• Section 3(d)
• Section 2(1)(j) (definition of invention)
• Section 2(1)(ja) (inventive step)
• Section 2(1)(ta) (pharmaceutical substance)

The Court noted that not all substances qualify as patent-eligible products. A substance becomes a patentable product only when it involves one or more inventive steps and demonstrates enhanced efficacy.

Importantly, the Division Bench clarified that Section 3(d) cannot be used as a defence to infringement. Once a patent is granted, infringement must be assessed independently of the patentability criteria under Section 3(d).

Polymorphs and Infringement

A central issue before the Court was Cipla’s claim that ERLOCIP was based on Polymorph B of Erlotinib Hydrochloride, whereas Roche’s patent covered Erlotinib Hydrochloride generally.

The Court examined the patent specification and held that:

• Erlotinib Hydrochloride may exist in several polymorphic forms
• The patent IN ’774 expressly stated that all polymorphic forms were subsumed within the patent

The Court observed that the preparation of Polymorph B necessarily involved the formation of Erlotinib Hydrochloride itself. Since Erlotinib Hydrochloride was the underlying compound in every polymorphic version, manufacturing a polymorph would still amount to infringement of the suit patent.

On this basis, the Division Bench concluded that Cipla’s ERLOCIP infringed Roche’s patent IN ’774.

Test for Patent Infringement

The judgement laid down important principles governing the test for infringement in patent cases.

The Court held that infringement is not established by merely examining the medical or clinical evaluation of the defendant’s product.

The correct approach is to compare the allegedly infringing product with the claims of the patent, not with the patentee’s marketed product.

The Court emphasised that claim construction lies at the heart of infringement analysis. In this case, the appropriate test was to map Cipla’s product against Roche’s patent claims.

A structured multi-step test for claim construction and infringement analysis was recognised, providing guidance for future patent infringement suits.

Final Decision

The Division Bench in F. Hoffmann-La Roche Ltd v Cipla Ltd ultimately held Cipla liable for infringement of Roche’s patent IN ’774.

Cipla was directed to:

• Render accounts of manufacture and sale of ERLOCIP
• Pay damages, to be determined by the Joint Registrar
• Pay costs of Rs. 5,00,000 to Roche

The Court did not grant a permanent injunction restraining Cipla from manufacturing the drug.

Conclusion

The Roche v Cipla dispute stands as a defining moment in Indian patent law. The Delhi High Court’s careful and detailed reasoning ensured that patent protection, innovation, and public interest were all addressed within the statutory framework. By reinforcing the importance of claim-based infringement analysis and clarifying the role of Section 3(d), the judgement continues to influence patent enforcement and interpretation in India.

Note: This article was originally written by Apoorva Pradhan (Amity Law School, Noida) and first published on 18 Sep 2022. It was subsequently updated by the LawBhoomi team on 23 January 2026.